Preloader

Foundation Medicine (Tissue + Liquid + RNA)

The Next Generation of Precision Oncology Is Now in Türkiye with FoundationOne® CDx

Samples are submitted through Nesiller Genetic to Foundation Medicine’s laboratories in the United States, where they are analyzed using an FDA-approved comprehensive genomic profiling (CGP) platform.

Key Features:

  • FDA-approved Companion Diagnostic (CDx) testing for all solid tumors, covering 300+ genes to support evidence-based, personalized treatment selection.
  • Identification and reporting of acquired resistance mechanisms, in addition to clinically relevant treatment options.
  • A combined tissue and liquid biopsy approach that increases the detection of clinically actionable genomic alterations associated with targeted therapies.
FeatureFoundationOne® CDxFoundationOne® Liquid CDxFoundationOne® RNA
Intended UseComprehensive genomic profiling for all solid tumors (Gold Standard)Minimally invasive comprehensive genomic profiling and complementary analysis when tissue biopsy is limited or unavailableAnalysis of clinically relevant RNA alterations
Sample TypeFFPE TissuePeripheral Whole Blood (2 Streck Tubes)FFPE Tissue
Analysis324 Genes + MSI + TMB + HRD324 Genes + MSI-H + bTMB*318 Genes (RNA Fusion Analysis)
Variant TypesSNVs, Indels, CNAs, RearrangementsSNVs, Indels, CNAs, Copy Number Loss (CNL), RearrangementsFusions, Rearrangements, Splice Variants
Additional FeaturesOptional PD-L1 IHCTumor Fraction ReportingIntegrated DNA + RNA Report
Turnaround TimeApproximately 2 weeksApproximately 2 weeksApproximately 2 weeks

* bTMB: Blood Tumor Mutational Burden.

 

//
Our customer support team is here to answer your questions!